



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 48/00, C12N 15/86, 15/49 // A61K 39/12, 39/18		A1	(11) International Publication Number: WO 96/40268 (43) International Publication Date: 19 December 1996 (19.12.96)		
(21) International Application Number: PCT/US96/08508		(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
(22) International Filing Date: 3 June 1996 (03.06.96)					
(30) Priority Data: 08/482,090 7 June 1995 (07.06.95) US					
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(72) Inventors: WASMOEN, Terri; 1506 13th Avenue North, Fort Dodge, IA 50501 (US). CHU, Hsien-Jue; 1506 13th Avenue North, Fort Dodge, IA 50501 (US). CHAVEZ, Lloyd, George, Jr.; 8502 S. Forrest Street, Highlands Ranch, CO 80126 (US).					
(74) Agents: MANDEL, Adley, F.; American Home Products Corporation, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.					
(54) Title: RECOMBINANT RACCOON POX VIRUSES AND THEIR USE AS AN EFFECTIVE VACCINE AGAINST FELINE IMMUNODEFICIENCY VIRUS INFECTION					
(57) Abstract					
<p>The present invention provides recombinant raccoon poxviruses (RRPVs) useful in vaccines for the prophylaxis of disease caused by feline immunodeficiency virus (FIV). RRPVs according to the invention have at least one internal gene comprising a DNA sequence that encodes FIV gag protein (<i>gag</i>), FIV enveloppe protein (<i>env</i>), a polypeptide consisting of amino acids 1-735 of FIV <i>env</i>, or immunogenic fragments of any of the foregoing. The vaccines that comprise one or more of the FIV-expressing recombinant raccoon poxviruses described above may also comprise a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. The invention also provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**RECOMBINANT RACCOON POX VIRUSES AND THEIR USE
AS AN EFFECTIVE VACCINE AGAINST FELINE
IMMUNODEFICIENCY VIRUS INFECTION**

FIELD OF THE INVENTION

The present invention pertains to the prophylaxis of disease caused by feline immunodeficiency virus (FIV), using as vaccines recombinant raccoon poxviruses (RRPVs) expressing the *gag* and envelope proteins of FIV.

BACKGROUND OF THE INVENTION

Feline immunodeficiency virus (FIV) infection is a significant health problem for domestic cats around the world. As in its human counterpart, infection with FIV causes a progressive disruption in immune function. In the acute phase of infection, the virus causes transient illness associated with symptoms such as lymphadenopathy, pyrexia, and neutropenia. Subsequently, an infected animal enters an asymptomatic phase of 1-2 years before clinical manifestations of immune deficiency become apparent, after which the mean survival time is usually less than one year.

FIV is a typical retrovirus that contains a single-stranded polyadenylated RNA genome, internal structural proteins derived from the *gag* gene product, and a lipid envelope containing membrane proteins derived from the *env* gene product (Bendinelli et al., *Clin. Microbiol. Rev.* 8:87, 1995). The *gag* gene is translated into a primary product of about 50 kDa that is subsequently cleaved by a viral protease into the matrix, capsid, and nucleocapsid proteins. The *env* gene yields a primary translation product of 75-80 kDa (unglycosylated molecular weight); in infected cells, the precursor has an apparent

molecular weight of 145-150 kDa due to N-linked glycosylation. The *env* precursor is cleaved in the Golgi apparatus into the SU and TM proteins (also designated gp95 and gp40, respectively).

Most vaccines against FIV have failed to induce protective immunity. Ineffective vaccines have involved inactivated whole virus, fixed infected cells, recombinant CA and SU proteins, and a synthetic peptide corresponding to the V3 region of SU. In some cases, the vaccine actually enhanced infection after challenge. In one system, vaccination with paraformaldehyde-fixed virus or infected cells resulted in protective immunity (Yamamoto et al., *J. Virol.* 67:601, 1993), but application of this approach by others was unsuccessful (Hosie et al., in *Abstracts of the International Symposium on Feline Retrovirus Research*, 1993, page 50).

Thus, there is a need in the art for an effective vaccine against FIV that utilizes the *gag* or *env* proteins, or fragments therefrom, as immunogens.

SUMMARY OF THE INVENTION

The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that result from FIV infection.

The invention provides recombinant raccoon poxviruses having at least one internal gene comprising a DNA sequence that encodes FIV gag protein (*gag*), FIV envelope protein (*env*), a polypeptide consisting of amino acids 1-735 of FIV *env*, or immunogenic fragments of any of the foregoing. By immunogenic fragment is meant any portion of the coding sequence of FIV *gag* or *env* polypeptides that induces a beneficial immune response in cats.

In another aspect, the invention encompasses vaccines that comprise one or more of the FIV-expressing recombinant raccoon poxviruses described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant.

In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphic illustration of the cloning strategy for the envelope gene of FIV.

Figure 2 is a diagrammatic representation of the structure of the recombinant FIV env gene in pSL-EnvABC.

Figure 3 shows the DNA [SEQ. I.D. NO. 14] and protein [SEQ. I.D. NO. 12] sequence of the *env* gene of FIV.

Figure 4 is a graphic illustration of the pSL-WGag plasmid.

Figure 5 shows the DNA [SEQ. I.D. NO. 13] and protein [SEQ. I.D. NO. 11] sequence of the *gag* gene of FIV.

Figure 6 is a graphic illustration of the cloning strategy for construction of the raccoon poxvirus transfer plasmid pSC11-FIV gag.

Figure 7 is a graphic illustration of the cloning strategy for construction of the raccoon poxvirus transfer plasmid pSC11-FIV Env.

Figure 8 is a graphic illustration of the cloning strategy for construction of the raccoon poxvirus transfer plasmid pSC11-FIV EnvAB.

Figure 9 is a table illustrating the detection of viremia and CD4:CD8 ratios in vaccinated and unvaccinated cats after FIV challenge.

Figure 10 is a table illustrating the preventable fraction for viremia and CD4:CD8 ratio changes in vaccinated and unvaccinated cats following FIV challenge.

Figure 11 is a table illustrating the clinical scores of vaccinated and unvaccinated cats after challenge with *Toxoplasma gondii*.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and references cited herein are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will control.

The vaccine of the present invention may be prepared by creating recombinant raccoon poxviruses (RRPVs) containing a gene encoding the *gag* or *env* proteins of Feline Immunodeficiency Virus (FIV) or immunogenic fragments thereof. *Gag* and *env* genes useful in practicing the present invention may be obtained by methods

well-known in the art. In one embodiment, viral RNA is reverse-transcribed using endogenous or exogenous reverse transcriptase and the DNA is rendered double-stranded using DNA polymerase. The *gag* and *env*-encoding DNA segments are then recovered by restriction enzyme digestion and are amplified by cloning in *E. coli*. In another embodiment, FIV-infected cat cells serve as a source of FIV proviral DNA. In this embodiment, chromosomal DNA is isolated from the cells, and oligonucleotide primers are used to specifically amplify the *gag* and *env* genes or fragments therefrom using polymerase chain reaction techniques. This approach is broadly applicable to purifying *gag* and *env* genes from different FIV strains or isolates, since primers can be designed from non-polymorphic regions of the FIV genome.

FIV *gag* and *env* genes isolated by the above methods are first inserted into a transfer plasmid, and the recombinant plasmid is introduced into appropriate host cells that have been previously infected with a raccoon poxvirus. As a result, the DNA from the transfer plasmid is incorporated into the poxvirus DNA by homologous recombination, producing the RRPVs that are released from the cells.

DNA encoding the FIV *gag* or *env* proteins or fragments therefrom are inserted into a transfer plasmid downstream of a poxvirus promoter. In a preferred embodiment, the early/late 7.5 kD protein promoter of vaccinia virus is used. However, alternate promoter elements could be used.

The preferred transfer plasmid also contains a beta-galactosidase marker gene, which allows for selection and detection of the plasmid DNA sequences in recombinant viruses. It will be understood by those of ordinary skill in the art that alternate selectable marker genes, such as the neomycin resistance gene or the *E. coli* *gpt* gene or others, could be used to practice the invention. Flanking the inserted FIV gene and the selectable marker gene are thymidine kinase DNA sequences, which facilitate integration of the plasmid DNA sequences into the raccoon poxvirus DNA by homologous recombination.

Recombinant viruses expressing the FIV *gag* or *env* genes are prepared by first infecting a susceptible cell line (such as Vero [ATCC CCL 81], BSC-1 [ATCC CCL 26], RAT-2 [ATCC CRL 1764], or CRFK [ATCC CCL 94]) with wild type raccoon poxvirus (ATCC VR-838 or similar isolates). Transfer plasmid DNA containing the FIV

gag or *env* gene is then transfected into the infected cells using cationic liposome-mediated transfection, or other suitable techniques such as electroporation or calcium-phosphate precipitation. Raccoon poxviruses incorporate DNA from the transfer plasmid through homologous recombination with the thymidine kinase gene sequences present on the plasmid. Virus infection is allowed to proceed until cytopathic effects are noted in all cells.

Incorporation of the FIV *gag* or *env* gene into poxvirus DNA is accompanied by disruption of the viral thymidine kinase gene. Thus, recombinant virus may be selected for by the absence of a thymidine kinase gene; this is achieved by selective expansion on RAT-2 cells (tk-, ATCC CRL 1764) in the presence of 5-bromodeoxyuridine. Viruses containing a gene insert from the transfer plasmid are identified by blue plaque color when grown in the presence of a chromogenic substrate for beta-galactosidase such as X-gal.

Viral plaques that survive these selection and screening procedures are then subjected to several cycles of plaque purification. Subsequently, the presence of the *gag* or *env* genes is confirmed by polymerase chain reaction technology, and the presence of *gag* or *env* antigenic determinant is confirmed by immunoblot analysis using specific antibodies. These viruses are designated by RRPV-FIV *gag* and RRPV-FIV *env*, respectively.

In a further embodiment of the present invention, RRPVs can be produced that express less-than-full-length segments of the FIV *gag* and *env* proteins. The techniques used to engineer transfer plasmids encoding partial sequences of *env* and *gag* are well-known and widely used in the art, as are the methods for production and screening of RRPVs as detailed in this specification. For example, convenient restriction enzyme recognition sites can be used to obtain fragments of either gene, as described, e.g., Example 1 below. Alternatively, introduction of oligonucleotides containing a stop codon at various points along *gag* or *env* DNA will produce a nested set of carboxyterminal-truncated versions of that gene, which can then be incorporated into RRPVs. Furthermore, sequences that encode different domains on each protein may be recombined, using domains derived from different FIV strains or isolates. It will be apparent to one of ordinary skill in the art that systematic screening of such recombinant

RRPVs can establish whether the intact protein, subfragments thereof or multi-strain recombinants thereof, are most preferred in practicing the present invention. Furthermore, as stated above, DNA encoding different fragments of *gag* and *env* can be used in a combination vaccine after incorporation into the same, or different, RRPVs.

For vaccine preparation, susceptible cells are grown in minimum essential media containing fetal bovine serum or a suitable media substitute. Cells are infected with recombinant raccoon poxvirus at a multiplicity of infection of 0.1 infectious units/cell or less. In this specification an infectious unit is defined as a Tissue Culture Infectious Dose (TCID₅₀), an amount of virus yielding 50% infection under defined conditions. When cytopathology is noted in >90% of the cells, the infected cells and extracellular fluids are harvested. The virus may be stored frozen (-50°C or colder) or lyophilized until the time of use. Compounds such as NZ-amine, dextrose, gelatin or others designed to stabilize the virus during freezing and lyophilization may be added. The virus may be concentrated using commercially available equipment.

Typically, the concentration of virus in the vaccine formulation will be a minimum of 10^{6.5} TCID₅₀ per dose, but will typically be in the range of 10^{7.0} to 10^{9.0} TCID₅₀ per dose. At the time of vaccination, the virus is thawed (if frozen) or reconstituted (if lyophilized) with a physiologically-acceptable carrier such as deionized water, saline, phosphate buffered saline, or the like.

In one embodiment, a physiologically acceptable adjuvant such as, for example, EMA31, Adjuvant A, or combinations thereof, is added to the vaccine formulation. Non-limiting examples of suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers such as Pluronic® (L121) Saponin; detergents such as Tween®-80; Quil® A, mineral oils such as Drakeol® or Marcol®, vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acne; Mycobacterium bovis (Bacillus Calmette and Guerinn, or BCG); interleukins such as interleukin 2 and interleukin-12; monokines such as interleukin 1; tumor necrosis factor; interferons such as gamma interferon; combinations such as saponin-aluminum hydroxide or Quil®-A aluminum hydroxide; liposomes; iscom adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine;

Lipid A; dextran sulfate; DEAE-Dextran or DEAE-Dextran with aluminum phosphate; carboxypolymethylene, such as Carbopol®; EMA; acrylic copolymer emulsions such as Neocryl® A640 (e.g. U.S. Patent 5,047,238); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; dimethyldioctadecylammonium bromide; or mixtures thereof.

EMA 31 (Monsanto, St. Louis, MO) is a linear ethylene/maleic copolymer with approximately equal amounts of ethylene and maleic anhydride, having an estimated average molecular weight of about 75,000 to 100,000. Adjuvant A is an adjuvant comprising a block copolymer, such as a polyoxypropylene-polyoxyethylene (POP-POE) block copolymer, preferably Pluronic® L121 (e.g. U.S. Patent 4,772,466), and an organic component, such as a metabolizable oil, e.g. an unsaturated turpin hydrocarbon, preferably squalane (2,6,10,15,19,23-hexamethyltetracosane) or squalene. The vaccine may also include a non-ionic detergent or surfactant, preferably a polyoxyethylene sorbitan monooleate such as a Tween® detergent, most preferably Tween®-80, i.e. polyoxyethylene (20) sorbitan monooleate.

In this adjuvant mixture, the block copolymer, organic oil, and surfactant may be present in amounts ranging from about 10 to about 40 ml/L, about 20 to about 80 ml/L, and about 1.5 to about 6.5 ml/L, respectively. In a preferred embodiment of the stock adjuvant, the organic component is squalane present in an amount of about 40 mL/L, the surfactant is polyoxyethylenesorbitan monooleate (Tween®-80) present in an amount of about 3.2 ml/L, and the POP-POE block copolymer is Pluronic® L121 present in an amount of about 20 mL/L. Pluronic® L121 is a liquid copolymer at 15-40°C, where the polyoxypropylene (POP) component has a molecular weight of 3250 to 4000 and the polyoxyethylene (POE) component comprises about 10-20%, preferably 10%, of the total molecule.

Individual raccoon poxviruses expressing the *gag* or *env* genes may be mixed together for vaccination. Furthermore, the virus may be mixed with additional inactivated or attenuated viruses, bacteria, or fungi, or with immunogens derived from viruses, bacteria, or fungi such as feline leukemia virus, feline panleukopenia virus, feline rhinotracheitis virus, feline calicivirus, feline infectious peritonitis virus, feline *Chlamydia psittaci*, *Microsporum canis*, or others. In addition, antigens from the above-cited

organisms may be incorporated into combination vaccines. These antigens may be purified from natural sources or from recombinant expression systems, or may comprise individual subunits of the antigen or synthetic peptides derived therefrom.

In a further embodiment of the present invention, live or inactivated RRPV virus-cell lysates can be incorporated into liposomes, or encapsulated in peptide-, protein-, or polysaccharide-based microcapsules prior to administration, using means that are known in the art. The vaccine of the present invention is administered to cats in volumes ranging from 0.5 to 5 milliliters. The vaccine can be administered to cats by subcutaneous, intramuscular, oral, intradermal, or intranasal routes. The number of injections and their temporal spacing may be varied. One to three vaccinations administered at intervals of one to three weeks are usually effective.

The efficacy of the vaccines of the present invention is assessed by the following methods. At about one month after the final vaccination, vaccinees and controls are each challenged with 3-20 cat ID₅₀ units, preferably 5 cat ID₅₀ units of FIV, preferably the NCSU1 isolate (ATCC VR-2333). Whole blood is obtained from the animals immediately before challenge, and at intervals after challenge, for measurement of a) viremia and b) relative amounts of CD4 and CD8 lymphocytes.

Viremia is measured by isolating mononuclear cells from the blood, and co-culturing the cells with mononuclear cells from uninfected animals. After 7 days of culture, the culture supernatants are tested for FIV by enzyme-linked immunoassay (See Example 5 below).

The ratio of CD4 to CD8 lymphocytes in the circulation of vaccinees and controls is taken as a measure of immune function. Typically, FIV infection causes an inversion of the normal CD4:CD8 ratio of about 1.5-4.0 to a pathological ratio of about 0.5-1.0. The numbers of CD4 and CD8 lymphocytes are measured by flow cytometry using specific antibodies (see Example 5 below).

Another measure of immune function is to challenge vaccinees and controls with *Toxoplasma gondii* at 6-12 months after the final RRPV-FIV vaccination. Normally, the severity of *T. gondii*- induced disease symptoms is considerably exacerbated in FIV-infected cats relative to uninfected cats. The severity of the *T. gondii* effect is determined by scoring ocular discharge, nasal discharge, dyspnea, and fever.

It will be understood that amelioration of any of the symptoms of FIV infection is a desirable clinical goal. This includes a lessening of the dosage of medication used to treat FIV-induced symptoms.

The following examples are intended to illustrate the present invention without limitation thereof.

Example 1: Cloning of FIV gag and env Genes

A. Isolation of Viral DNA

FIV strain NCSU-1 (designated "FIV-NCSU-1") was isolated from a naturally infected, feline leukemia virus-negative cat and has been described previously (Tompkins et al., *J. Am. Vet. Med. Assoc.* 199: 1311, 1991). The virus was passed in a normal specific pathogen-free (SPF) cat (obtained from Liberty Laboratories, Waverly, NY). FIV-infected peripheral blood mononuclear cells (PBMC) were obtained from whole blood by separation on discontinuous percoll gradients. Briefly, anti-coagulated whole blood was layered over a two step gradient containing 43% Percoll™ (Pharmacia, Piscataway, NJ) over 62.5% Percoll™ in 0.15 M NaCl. Gradients were centrifuged at 400 x g for 5 minutes, followed by 800 x g for 20 minutes at 22°C. PBMC were harvested from the gradient interface and washed in phosphate buffered saline containing 5% fetal bovine serum. In parallel, PBMCs were isolated from normal cats.

FIV was propagated by co-culture of PBMCs from an FIV-infected cat with PBMCs from normal cats. The cells were maintained in RPMI 1640 media containing 10% fetal bovine serum, 2.5×10^{-5} beta-mercaptoethanol, 2 mM L-glutamine, 5 µg/mL concanavalin A, and 20% conditioned media from MLA cells (ATCC TIB 201) as a source of interleukin-2 (IL-2).

Cat genomic DNA containing FIV-NCSU-1 proviral sequences was isolated from the cultured PBMCs by lysis of the cells with 0.6% sodium dodecyl sulfate (SDS) in 10 mM Tris-HCl, pH 7.5, 10 mM EDTA, followed by precipitation of chromosomal DNA by incubation overnight with 1 mM NaCl. The DNA was recovered by centrifugation at 10,000 r.p.m. (Beckman J2, JA-20 rotor) for 40 minutes. The DNA pellet was resuspended in a solution containing 10 mM Tris-HCl pH 7.5, 10 mM EDTA, 0.1% SDS buffer and digested with ribonuclease A (20 µg/ml) and proteinase K (0.2

mg/ml) at 50°C for 4 hours. DNA was then purified by sequential extraction with phenol, phenol:chloroform (1:1) and chloroform, and was recovered in pure form followed by ethanol precipitation.

B. Cloning of FIV Envelope Gene

FIV-NCSU-1 envelope DNA sequences were cloned using polymerase chain reaction (PCR) methods as follows:

Envelope Fragment A

The following oligonucleotides were used to amplify the 5' proximal segment of the *env* gene.

5'-TCGGATCCAACAATAATTATGGCAGAAGG-3' [SEQ. I.D. NO. 1] (Coding strand, 6252-V)

5'-AATCAGGTACAAAGTCACCGTTC-3' [SEQ. I.D. NO. 2] (Complementary strand, 6745-C)

Primer 6252-V corresponds to nucleotides 6252-6273 of FIV strain PPR (GenBank No. M36968) and primer 6745-C (underlined region) corresponds to nucleotides 6723-6745 of FIV strain 14 (GenBank No. 25381). The start codon for envelope protein translation is included in primer 6252-V. Primer 6252-V also has a synthetic BamHI restriction enzyme site near the 5' end to facilitate cloning. An AvrII site located at position 6719 also facilitates cloning. Envelope fragment A is 494 bp in length.

Envelope Fragment B

The following oligonucleotides were used to amplify the middle segment of the *env* gene.

5'-TATAGAACCCCCAAGAAGAG-3' [SEQ. I.D. NO. 3] (Coding strand, 6637-V)

5'-CATCCCCAAAGTTATATTC-3' [SEQ. I.D. NO. 4] (Complementary strand, 8469-C)

Primers 6637-V and 8469-C correspond to nucleotides 6637-6659 and 8448-8469 of FIV 14 strain, respectively. An AvrII site at position 6719 and a SpeI site at position 8288 facilitated cloning. Envelope fragment B is 1833 bp in length.

Envelope Fragment C

The following oligonucleotides were used to amplify the 3' distal fragment of the *env* gene.

5'-TTAGTTACATTAGAGCATCAAG-3' [SEQ. I.D. NO. 5] (Coding strand, 8264-V)
5'-TTCTAGATCTTCAGGGTCCCAATACTC-3' [SEQ. I.D. NO. 6] (Complementary strand, 9145-C)

Primer 8264-V corresponds to nucleotides 8264-8285 of FIV strain 14, and primer 9145-C (underlined region) corresponds to nucleotides 9126-9145 of FIV strain PPR. Primer 9145-C has a synthetic BglIII site near the 5' end to facilitate cloning. An SpeI site located at position 8288 also facilitated cloning. Envelope fragment C is 880 bp in length.

In each case, PCR was performed for 35 cycles of 1 min 30 sec at 94°C, 2 min at 56°C, and 2 min at 72°C, followed by one cycle of 8 min at 72°C. Each envelope fragment was isolated by gel electrophoresis and cloned into plasmid pSL1190 using standard methods (Maniatis et al., *Molecular Cloning: A Laboratory Manual*, 1982, Cold Spring Harbor Press).

Initially, each fragment was cloned into pSL1190, after which the three fragments were spliced together to re-create a full length envelope gene. For this purpose, the Envelope A plasmid was digested with BamHI and AvrII, the envelope B plasmid was digested with AvrII and SpeI, and the envelope C plasmid was digested with SpeI and BglIII. Subsequently, the 1.5 kbp AvrII/SpeI envelope B fragment was ligated into pSL-EnvA that had been digested with AvrII and SpeI to create pSL-EnvAB (Figure 1). The *envAB* fragment codes for the entire surface membrane protein (SU) and the first 63 amino acids from the amino-terminus of the transmembrane protein (TM) of FIV-NCSU-1, i.e., amino acids 1 - 735 of *env*. However, *envAB* does not contain the transmembrane domain (TM).

Next, the 0.9 kbp SpeI/SmaI envelope C fragment from pSL-EnvC was ligated into pSL-EnvAB that had been digested with SpeI and BbrPI, to create pSL-EnvABC or pSL-WEnv (Figure 1). The WEnv fragment codes for the entire *env* open reading frame (SU and TM proteins) of FIV NCSU-1 (Figure 2).

The subcloned genetic elements of FIV-NCSU-1 were sequenced using Sequenase Version 2.0 (United States Biochemical, Cleveland, OH)) as described for double-stranded DNA, and the reactions were analyzed using the ABI automated sequencer (Applied Biosystems, Foster City, CA). Both DNA strands were sequenced to confirm the results. The DNA sequences were analyzed using the MacVector DNA Analysis software (International Biotechnologies, Inc., New Haven, CT). The *env* DNA sequences were analyzed for open reading frames and compared to the previously published DNA sequences of other FIV isolates. The DNA and predicted amino acid sequences of *env* and *envAB* open reading frames of FIV-NCSU-1 are shown in Figure 3.

C. Cloning of The FIV GAG Gene

The *gag* gene of FIV-NCSU₁ was amplified using PCR and the following oligonucleotide primers:

5'-CAATTCTAGAGAGACTCTACAGAACATG-3' [SEQ. I.D. NO. 7] (Coding strand, 610-V)

5'-TAATAGATCTGGCCTCTTCTAATGATG-3' [SEQ. I.D. NO. 8] (Complementary strand, 2026-C)

Primers 610-V and 2026-C correspond to nucleotides 610-630 and 2005-2026 of FIV 14 strain, respectively. Primers 610-V and 2026-C have XbaI and BglII restriction enzyme sites, respectively, near their 5' ends to facilitate cloning. The last three nucleotides of primer 610-V correspond to the start codon for *gag* protein translation. PCR was performed for 35 cycles of 1 min 30 sec at 94°C, 2 min at 56°C, and 2 min at 72°C, followed by one cycle of 4 min at 72°C. The 1.4 kbp DNA fragment containing the *gag* gene was purified by gel electrophoresis and cloned into the XbaI/BglII site of pSL1190 to form pSL-WGag (Figure 4). The DNA sequence of FIV-NCSU-1 *gag* is shown in Figure 5.

Example 2: Preparation of Recombinant Raccoon Poxviruses

A. Construction of Raccoon Poxvirus Transfer Plasmids

The DNA sequences encoding the *gag*, *env*, and *envAB* isolated as described in Example 1 were individually subcloned into the poxvirus transfer vector pSC11. The sequence of pSC11 is disclosed in co-pending U.S. patent application Serial

No. 08/125,516, which is incorporated by reference. For this purpose, the 1.4 kb XbaI/BglII fragment of pSL-WGag (Figure 6), the 2.9 kb BamHI/SpiI fragment of pSL-WEnv (Figure 7) and the 2.1 kb BamHI/SpeI fragment of pSL-EnvAB (Figure 8) were individually isolated and rendered blunt-ended with the Klenow fragment of DNA polymerase, after which each was individually cloned into the SmaI site of pSC11.

B. Preparation of Recombinant Raccoon Poxviruses

Recombinant raccoon pox viruses (RRPV) bearing the FIV *gag* and *env* genes were prepared as generally described for recombinant vaccinia viruses (Mackett and Smith, *J Gen Virol* 67:2067-2082, 1986) with some modifications. Monolayers of Vero cells (ATCC CCL 81) that were 80% confluent (approximately 5×10^6 cells in 100 mm tissue culture dishes) were infected with wild-type raccoon pox virus (ATCC VR-838) at a multiplicity of infection (MOI) of 0.1 TCID₅₀/cell in 2 ml of MEM (Eagle's Minimum Essential Medium (Gibco BRL #410-1500) containing 0.05% lactalbumin hydrolysate and 15 µg/ml gentamicin sulfate, adjusted to pH 7.2 with sodium bicarbonate) for 30-60 minutes at 37°C. The cells were then transfected with either pSC11-FIV *gag*, pSC11-FIV *env*, or pSC11-FIV *env AB* transfer plasmids by cationic liposome-mediated transfection using Transfectam® (Promega Corporation, Madison, Wisconsin) according to manufacturer's instructions. The cells/DNA-liposomes mixture was incubated in 3 ml of MEM containing 5% fetal bovine serum (FBS) overnight at 37°C (5% CO₂), after which the medium was replaced with 8 ml fresh MEM/5% FBS. The transfected cells were incubated at 37°C (5% CO₂) until greater than 80% of the cells showed cytopathic effects (approximately 3-4 days). The cells and culture media (viral-cell lysates) were then removed from the plates and subject to two cycles of freeze-thawing before storage at -70°C.

C. Isolation of Recombinant Raccoon Pox Virus Carrying the FIV *gag* Gene

RRPV carrying the FIV-NCSU₁ *gag* gene (RRPV-FIV *gag*) are isolated and purified from the pSC11-FIV *gag*/Vero cell transfection by standard viral plaque assay methods. Monolayers of Vero cells (50-80% confluent) in 100 mm tissue culture dishes were

infected with 2 ml of 10-fold serial dilutions (10^{-1} to 10^{-3} in MEM) of the viral-cell lysates. After incubation, for 1 hour at 37°C, the media are removed and the infected cells were overlaid with 8-10 ml of 1.25% Noble agar containing MEM/5% FBS. The infected cells were then incubated for 3-4 days at 37°C (5% CO₂), and overlaid again with 4 ml of 1.25% Nobel agar containing 0.5X PBS and 600 ug/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal, United States Biochemical, Cleveland, Ohio). The plates were incubated at 37°C (5% CO₂) for 4-16 hours, until blue viral plaques (β-galactosidase positive) were observed. The recombinant viral plaques were picked with sterile blunt needles attached to a 1 cc syringe, suspended in 0.5 ml of 0.25 mg/ml trypsin, vortexed vigorously, and incubated at 37°C for 15-30 minutes. The disrupted viral plaques were then inoculated onto 5×10^5 Vero cells in T-25 cm² flasks and incubated at 37°C (5% CO₂) until greater than 80% CPE was observed. The viral-cell lysates containing RRPV-FIV gag were subjected to two cycles of freeze-thawing and stored at -70°C. Five individual RRPV-FIV gagclones were selected and plaqued purified four times as described above.

D. Isolation of Recombinant Raccoon Pox Virus Carrying FIV envAB Gene

RRPV carrying the FIV-NCSU₁ envAB gene (RRPV-FIV envAB) were isolated and purified from the pSC11-FIV envAB/Vero cell transfection using the methods as described for RRPV-FIV gag with some slight modifications. Thymidine kinase deficient (tk-) raccoon pox viruses from the initial viral-cell lysates were selected on tk- Rat-2 cells (ATCC CRL 1764). This was performed by inoculating 1 ml of the initial viral-cell lysate onto a monolayer of Rat-2 cells in a T-75 cm² flask (approximately 5×10^6 cells) containing 5-bromodeoxyuridine (BrdU) at 30 ug/ml in MEM. The infected monolayer was incubated at 37°C (5% CO₂) for 3-4 days until greater than 70% CPE was observed. The tk- viral-cell lysates were subjected to two cycles of freeze-thawing two times and stored at -70°C. RRPV-FIV envAB were isolated and purified from the tk- viral-cell lysates by the standard viral plaque assay as described above for RRPV-FIV gag on Vero cells. Five individual RRPV-FIV env AB clones were selected and plaque purified five times.

Example 3: Characteristics of Recombinant FIV-Expressing Raccoon Pox Viruses**A. Confirmation of FIV *gag* and *envAB* Genes in RRPV by Polymerase Chain Reaction**

The presence of the FIV *gag* and *envAB* genes in the RRPVs was confirmed using PCR. 90 μ l of a viral-cell lysate was incubated with 10 μ l of 10X PCR lysis buffer (1X; 10 mM Tris-HCl buffer, pH 8.5, containing 50 mM KCl, 2.5 mM MgCl₂, 0.5% Tween 20, 0.3 mg/ml Proteinase K) for 16 hours at 50°C, then boiled for 10 minutes. 10 μ l of this lysate was used as a template in the PCR reaction. PCR was performed in 100 μ l of 10 mM Tris-HCl buffer, pH 8.3, containing 50 mM KCl, 200 μ M of each dNTP, 1.5 mM MgCl₂, 30 pmoles of each primer, and 2.5 Units of AmpliTaq® DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT). The primers used in the PCR for FIV *gag* were:

5'-TATGGAAAAGGCAAGAGAAGGAC-3' [SEQ. I.D. NO. 9]

5'-TCGAGATACCATGCTCTACACTG-3', [SEQ. I.D. NO. 10]

corresponding to nucleotides 471-493 and 763-785 of the FIV *gag* open reading frame, respectively. The primers used in the PCR for FIV *envAB* were:

5'-TATGGAAAAGATGGGATGAGACTA-3' [SEQ. I.D. NO. 15]

5'-GTCACTTACCTTCATAGTAAACC-3' [SEQ. I.D. NO. 16]

corresponding to nucleotides 857-880 and 1513-1535 of the FIV *env* open reading frame, respectively. The PCR amplifications were performed in a DNA Thermal Cycler (Perkin-Elmer Cetus) by first heating the reaction mixes to 94°C for denaturation, and then 35 cycles of 1 minute at 95°C, 1 minute at 55°C, and 2 minutes at 72°C, and a final incubation of 8 minutes at 72°C. 10 μ l of the PCR products were analyzed by electrophoresis in a horizontal-submarine 4% NuSieve® agarose (FMC BioProducts, Rockland, ME) gel in TAE buffer (40 mM Tris base, 20 mM sodium acetate, 1 mM EDTA, pH 7.2) by applying 5 V/cm for 1-2 hours, and staining with ethidium bromide. PCR amplifications with the FIV *gag* and *env* primers gave expected DNA fragments of 314 and 678 nucleotides, respectively. PCR amplifications using the pSC11 FIV *gag* and *envAB* transfer plasmids served as positive controls. PCR amplifications using wild-type raccoon pox virus-Vero cell lysates served as a negative control.

B. Confirmation of RRPV FIV gag and envAB Protein Expression by Western Blot Analysis

Confluent monolayers of Vero cells in a T-25 cm² flask (1-2 x 10⁶ cells) were infected with clones of either RRPV-FIV *gag* or RRPV-FIV *envAB* at an M.O.I. of 1 to 10 TCID₅₀ per cell. The infected cells were incubated at 37°C (5% CO₂) for 2-3 days until approximately 80% CPE was observed. 20 µl of the viral-cell lysate was added to 5 µl of 5X Laemmli sample buffer (0.3 M Tris-HCl buffer, pH 6.8, containing 5% SDS, 50% glycerol, 0.4% bromophenol blue, and 3% 2-mercaptoethanol) and heated at 95°C for 5 minutes. The denatured protein samples were separated by SDS/polyacrylamide electrophoresis using a 4-15% gradient polyacrylamide gel (Maniatis et al., Molecular Cloning: A Laboratory Manual, 1982, Cold Spring Harbor Press). After electrophoresis, the proteins were transferred to nitrocellulose filters (Bio-Rad Laboratories, Hercules, CA) by electrotransfer using a Bio-Rad transfer apparatus per manufacturer's instructions. The transfer was performed in 25 mM Tris-HCl buffer, containing 0.2 M glycine and 20% methanol, for 45 minutes at 50V with constant current.

The blot was then screened for FIV *gag* and *envAB* proteins by immunoblot analysis as previously described (Davis et al., *Basic Methods in Molecular Biology*, 1986, Elsevier Science Publishing Company, New York, NY) with some slight modifications. After transfer, the nitrocellulose blot was rinsed in phosphate buffer saline, pH 7.4, containing 0.1% Tween-20 (PBS-TW), and non-specific sites were blocked by incubating the blot in PBS containing 1% bovine serum albumin (PBS-BSA) at 4°C overnight, followed by a 15 minute wash in PBS-TW. The blot was then incubated for 30 minutes at room temperature with goat anti-FIV IgG diluted 1:100 in PBS-TW containing 1% BSA (PBS-TW-BSA), followed by four 5 minute washes in PBS-TW. Next, the blot was incubated for 30 minutes at room temperature with a biotin-labeled mouse-anti-goat IgG antibody (secondary antibody) (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) diluted 1:2000 in PBS-TW-BSA, followed by four 5-minute washes in PBS-TW. Antigen-antibody complexes were detected by, incubating the blot for 30 minutes at room temperature with horseradish peroxidase-conjugated streptavidin (Kirkegaard & Perry Laboratories Inc.) diluted 1:1000 in PBS-TW, washing four times for 5 minutes each in PBS-TW, and visualizing with peroxidase chromogenic substrate (Kirkegaard & Perry

Laboratories Inc.). Sucrose-gradient purified FIV and wild-type raccoon pox virus/Vero cell lysates were used as the positive and negative controls for the immunoblot analysis, respectively.

Goat anti-FIV antibodies were prepared as follows. FIV NCSU₁ was grown in peripheral blood lymphocytes and concentrated using a hollow fiber apparatus to a concentration of about 10^6 TCID₅₀/ml. The concentrated virus stock was mixed with an oil adjuvant such as OW3 in a ratio of 1:1 (v:v), and the emulsion was used to inoculate goats six times, at intervals of 3-4 weeks. At monthly intervals, the goats were bled and the serum was tested for the presence of anti-FIV antibodies.

C. Confirmation of RRPV FIV gag and envAB Protein Expression by Immunofluorescence Assay

Confluent monolayers of Vero cells in 96-well plates ($1-2 \times 10^4$ cells/well) are infected with clones of either RRPV-FIV *gag* or RRPV-FIV *envAB* at a multiplicity of infection of 0.1 to 1.0 plaque forming units per cell. Cell infected with wild-type RCNV serve as a negative control. The infected cells are incubated at 37°C (5% CO₂) for 1 day until approximately 20% CPE is observed. The cells are then washed three times with PBS and fixed with 80% acetone at 4°C for ten minutes. Next, the cells are rehydrated with PBS and incubated with a monoclonal antibody (IgG) against either FIV *gag* or *env* surface membrane proteins for 30 minutes at room temperature. FIV antigen/FIV antibody complexes are detected using a FITC-conjugated goat anti-mouse IgG (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) and fluorescence microscopy.

D. Raccoon Poxvirus Titration

Virus preparations were pre-treated by dilution into an equal volume of 0.5% trypsin and incubation at 37°C for 30 minutes in order to release virus from inclusions. Serial dilutions (10-fold) of virus were then prepared in MEM and were inoculated (100 µl/well) in replicates of five onto Vero cells (1×10^4 cells in 100 µl per well) in a 96 well plate. Plates were incubated for 3-5 days at 37°C (5% CO₂) and observed for cytopathology typical of raccoon poxvirus. Viral infectivity titers were calculated as 50% endpoints based on cytopathology using the methods of Reed and Muench (Reed and Muench, *The American Journal of Hygiene* 27: 493, 1938).

Example 4: Preparation of Vaccines Based on Recombinant Pox Viruses**A. Preparation of Master Seeds of RRPV-FIV gag and envAB Viruses**

A single clone of each recombinant virus that showed significant recombinant protein expression (by the method described in Example 3 above) was selected for large-scale expansion to serve as a master seed virus. All recombinant virus expansions and titrations were done on Vero cells in MEM containing 2.5% FBS. Each plaque-purified virus clone was expanded by inoculating a confluent monolayer of Vero cells in a T-150 cm² flask (1×10^7 cells) with 1 ml of viral-cell lysate (approximately 10^7 infectious virus particles), and incubating at 37°C (5% CO₂) until 100% CPE was observed (2-3 days). This viral-cell lysate served as a pre-master seed virus stock and was used to obtain the master seed virus. The pre-master seed of each recombinant virus was titrated on Vero cells and a TCID₅₀ was determined. The master seed viruses for RRPV-FIV *gag* and RRPV-FIV *envAB* were grown on Vero cells using an MOI of 0.01 and 0.1, respectively. Three roller bottles of confluent Vero cells were infected for each of the master seed viruses using MEM media supplemented with 2.5% fetal bovine serum and incubated for approximately 3 days at 37°C. Infected culture supernatant fluids were harvested, and seed viruses were aliquoted into 1.5 ml ampules, which were sealed and stored in a liquid nitrogen freezer.

B. Preparation of Vaccines

Vero cells (3×10^7) were seeded into 850 cm² roller bottles in 200 ml of growth media (MEM containing 0.5% lactalbumin hydrolysate and 5% heat-inactivated fetal bovine serum) and incubated for 18 hours at 37°C. The next day, the media were removed from the cells and replaced with 50 ml of RRPV-FIV *gag* at a multiplicity of infection of 0.01 in infection media (MEM containing 0.5% LAH and 2.5% heat-inactivated fetal bovine serum). The virus used was at the fourth passage beyond the master seed preparation. Virus was allowed to adsorb to the cells for 30 minutes at 37°C, after which the volume of medium was adjusted to 150 ml per roller bottle. Roller bottles were incubated at 37°C until 100% cytopathology was evident (3 days). A virus/cell

lysate was then prepared and stored frozen (-70°C). The virus titer of RRPV-FIV *gag* was determined to be $10^{7.4}$ TCID₅₀/ml.

Recombinant raccoon poxviruses expressing the FIV *envAB* gene fragment were prepared in the same manner, except that a multiplicity of infection of 0.1 was used. The virus was at the fourth passage beyond the master seed preparation. The RRPV-FIV *envAB* preparation was titered and found to contain $10^{6.4}$ TCID₅₀/ml.

Wild type raccoon poxvirus was grown using the same methods as described above. This virus preparation was found to contain $10^{7.7}$ TCID₅₀/ml.

Example 5: Test of Efficacy of FIV Vaccines Based on Recombinant Pox Viruses

A. Vaccination

Thirty 6-7 month old cats (specific pathogen-free, Harlan Sprague Dawley, Madison, WI), fifteen males and fifteen females, were used. Cats were divided into six groups and vaccinated twice, 21 days apart, as indicated below:

Table 1. Assignment of Groups for Vaccination

Group	# Cats	Vaccine	Volume	Virus Dose(TCID ₅₀)	Route
1	5	RRPV-FIV <i>gag</i>	1 mL	$10^{7.4}$	SC
2	5	RRPV-FIV <i>gag</i>	1 mL	$10^{7.4}$	IM
3	5	RRPV-FIV <i>envAB</i>	3 mL	$10^{6.9}$	SC
4	5	RRPV-FIV <i>envAB</i>	2 mL	$10^{6.7}$	IM
5	5	RRPV-FIV <i>gag</i> (1 ml) + RRPV-FIV <i>envAB</i>	4 mL	$10^{7.4}$ (<i>gag</i>) $10^{6.9}$ (<i>envAB</i>)	SC
6	5	Wild Type raccoon pox virus	1 mL	$10^{7.7}$	SC

* SC = Subcutaneous Vaccination
IM = Intramuscular Vaccination

B. Experimental Design

Twenty-five cats were vaccinated with the recombinant raccoon poxvirus vaccines as indicated in Table 1. Five cats were administered a similar titer of wild type raccoon poxvirus to serve a negative controls. Two vaccinations were administered 21 days apart. Subcutaneous vaccinations were administered in the nape of the neck, and intramuscular vaccinations were administered in a rear thigh. Four weeks following the second vaccination, all cats were challenged with the NCSU-1 strain of FIV and monitored for viremia and evidence of lymphocyte population changes as described below. Eleven months following FIV challenge, cats in Groups 1, 2, 3, 4, and 6 were challenged with *Toxoplasma gondii* and monitored for 48 days for clinical signs of disease.

C. FIV Challenge

Four weeks following the second vaccination, all of the cats were challenged subcutaneously with 10 cat ID₅₀ units of the NCSU₁ isolate of FIV(1:1000 dilution of lot # 021891). Whole blood was obtained from the cats prior to challenge, and periodically after challenge, in order to assess virus infection parameters as follows:

1. Detection of Viremia

Culture isolation of FIV was performed as described previously (Wasmoen et al., *Vet. Immuno. Immunopath.* 35:83 1992). Mononuclear cells were isolated from whole blood using Percoll™ (Pharmacia Biotech, Piscataway NJ) gradients. 5 x 10⁵ cells from FIV-challenged cats were cultured with 1 x 10⁶ mononuclear cells isolated from uninfected cats. Cultures were fed with RPMI media every 7 days and supernatants tested for the presence of FIV by an enzyme-linked immunosorbent assay (ELISA) that detects FIV p25 antigen (Petcheck ELISA, IDEXX, Portland ME).

2. Lymphocyte Subsets

Leukocytes were isolated from whole blood using Histopaque™ (Sigma Chemical Company, St. Louis MO) and lymphocyte subsets quantitated by staining the cells with antibodies specific to CD4 (monoclonal antibody CAT30A), CD8 (monoclonal

antibody FLSM 3.357), pan T lymphocytes (monoclonal antibody FLSM 1.572) or B lymphocytes (anti-cat IgG) followed by FACS analysis. These monoclonal antibodies are described elsewhere (Tompkins et al. *Vet. Immunol. Immunopathol.* **26**:305, 1990) and the flow cytometry procedure is the same as previously described (R.V. English et al. *J. Infect. Dis.* **170**:543, 1994). CD4:CD8 ratios were calculated.

D. ***Toxoplasma gondii* Challenge**

Tachyzoites of the ME49 strain of *T. gondii* that were frozen in 10% glycerol were inoculated intraperitoneally into Swiss mice (Charles Rivers Laboratories) and serially passed in mice according to published procedures (Davidson et al., *Am. J. Pathol.* **143**:1486, 1993). Tachyzoites harvested from peritoneal fluids of mice were enumerated using a hemacytometer. Cats were tranquilized using ketamine hydrochloride and inoculated with 50,000 fresh tachyzoites into the right common carotid artery that had been surgically isolated. Cats were monitored for clinical signs of disease, including ocular discharge, nasal discharge, dyspnea, fever, depression, and weight loss for 3 days prior to and 48 days following *T. gondii* inoculation.

Clinical signs follow *T. gondii* challenge were scored as follows:

Clinical Sign	Score
Fever	103.0 to 103.9°F 1 point per day
	104.0 to 104.9°F 2 points per day
	≥105.0°F 3 points per day
<i>(Temperatures were not scored until ≥1°F above baseline.)</i>	
Depression/Lethargy	1 point per day
Dehydration	2 points per day
Nasal Discharge	1 point per day
Ocular Discharge	1 point per day
Respiratory Distress:	
Tachypnea	2 points per day
Dyspnea	4 points per day

E. RESULTS

At one month following inoculation with the NCSU-1 strain of FIV, 60% of the control cats were found to be viremic (Figure 9). Cats vaccinated with RRPV-FIV *gag* were all negative for FIV, 40% of the cats vaccinated with RRPV-FIV *envAB* were virus positive, and 20% of the cats vaccinated with a combination of these two viruses were viremic (Figure 9). Therefore, the ability of the test vaccines to prevent viremia at this time point varied from 33% to 100% (Figure 10).

At three months after FIV challenge, 80% of the control cats were found to be virus positive (Figure 9). Similarly, FIV could be isolated from peripheral blood mononuclear cells of nearly all vaccinated cats using this very sensitive method (Figure 9).

With respect to immune status, 80% of the control cats showed evidence of CD4:CD8 lymphocyte ratio inversions (i.e. ratios less than 1.0) at three months (Figure 9). In contrast, only 30% of the RRPV-*gag* vaccinated cats had evidence of significant CD4:CD8 inversions, and the RRPV-FIV *envAB* vaccines were similarly protected from this lymphocyte subset change (Figure 9). Cats vaccinated with a combination of the two recombinant viruses were not significantly different from the controls (i.e. 80% showed CD4:CD8 inversions) at 3 months after challenge (Figure 9).

At 9 months after FIV challenge, 100% of the control cats were FIV infected, and all showed CD4:CD8 inversions (Figure 9). A large percentage of the vaccinated cats were also shown to be viremic at this time point. However, only 50% of the RRPV-FIV *gag* vaccines and 20% of the RRPV-FIV *envAB* vaccines showed evidence of CD4:CD8 inversions at this time point. *Therefore, these two vaccines showed a significant ability to prevent the CD4:CD8 lymphocyte ratio changes associated with FIV infection even though the cats appeared to be viremic (Figure 10).*

In order to determine whether CD4:CD8 lymphocyte subset inversions signified a deterioration in the immune system of cats following FIV infection (and, conversely, that lack of inversion in vaccines signified maintenance of immune function), vaccinated and control cats (from groups 1, 2, 3, 4, and 6) were challenged with *Toxoplasma gondii*. This parasite causes subclinical infections in normal cats, but has been reported to cause severe disease in cats that are immunocompromised due to FIV

infection (Davidson et al., *Am. J. Pathol.* **143**:1486, 1993). Following *T. gondii* challenge, control cats displayed ocular discharge, nasal discharge, dyspnea, and fever. The average total clinical score for control cats was 15.6 (Figure 11). By comparison, there was a 41% reduction in clinical disease scores in RRPV-FIV *gag* vaccinated cats, related to reductions in clinical signs of ocular discharge and dyspnea (Figure 11). The clinical picture following *T. gondii* challenge was even less severe in RRPV-FIV *envAB* vaccinated cats. This group showed a 92% decrease in ocular signs, 75% decrease in nasal discharge, 73% reduction in dyspnea, and 58% decrease in overall clinical scores (Figure 11). Further, 80% of the control cats displayed weight loss in the first 14 days after challenge, compared to weight loss in only 44% of the RRPV-FIV *gag* vaccinees and 50% of the V-FIV *envAB* vaccinees. Therefore, control cats were more susceptible to induction of disease by this opportunistic pathogen than vaccinated cats.

These data suggest that vaccination altered the progression of clinical disease caused by this virus (i.e. induction of immune suppression). This is indicated by a lower rate of CD4:CD8 inversions in vaccinated cats and by a decreased susceptibility to infection with the opportunistic pathogen *T. gondii*.

What is claimed is:

1. A recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding the envelope protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom.
2. The recombinant raccoon poxvirus of claim 1 wherein said internal gene encodes the FIV envelope protein having the amino acid sequence as set out in Figure 3 or immunogenic fragments therefrom.
3. The recombinant raccoon poxvirus of claim 2 wherein said internal gene encodes amino acids 1-735 of the FIV envelope protein.
4. A vaccine comprising:
 - a recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding envelope protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom, and
 - a pharmaceutically acceptable carrier or diluent.
5. The vaccine of claim 4 further comprising a pharmaceutically acceptable adjuvant.
6. The vaccine of claim 6 wherein said internal gene encodes the FIV envelope protein having the amino acid sequence as set out in Figure 3 or immunogenic fragments therefrom.
7. The vaccine of claim 4 wherein said internal gene encodes amino acids 1-735 of the FIV envelope protein.
8. The vaccine of claim 4 further comprising immunogens derived from viruses selected from the group consisting of feline leukemia virus, feline

panleucopenia virus, feline rhinotracheitis virus, feline calicivirus, feline infectious peritonitis virus, feline herpesvirus, feline enteric coronavirus, or mixtures thereof.

9. The vaccine of claim 4 further comprising inactivated or attenuated feline *Chlamydia psittaci*, *Microsporum canis*, or mixtures thereof.

10. A recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding the gag protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom.

11. The recombinant raccoon poxvirus of claim 10 wherein said internal gene encodes the FIV gag protein having the amino acid sequence as set out in Figure 5 or immunogenic fragments therefrom.

12. A vaccine comprising:

a recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding gag protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom, and

a pharmaceutically acceptable carrier or diluent.

13. The vaccine of claim 12 further comprising a pharmaceutically acceptable adjuvant.

14. The vaccine of claim 12 wherein said internal gene encodes the FIV gag protein having the amino acid sequence as set out in Figure 5 or immunogenic fragments therefrom.

15. The vaccine of claim 12 further comprising immunogens derived from viruses selected from the group consisting of feline leukemia virus, feline panleucopenia virus, feline rhinotracheitis virus, feline calicivirus, feline infectious peritonitis virus, feline herpesvirus, feline enteric coronavirus, or mixtures thereof.

16. The vaccine of claim 12 further comprising inactivated or attenuated feline *Chlamydia psittaci*, *Microsporum canis*, or mixtures thereof.

17. A vaccine comprising:

a first recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding a member selected from the group consisting of the *gag* and envelope proteins of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom;

a second recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding a member selected from the group consisting of the *gag* and envelope proteins of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom; and

a pharmaceutically acceptable carrier or diluent.

18. The vaccine of claim 17 further comprising a pharmaceutically acceptable adjuvant.

19. A method for preventing or lessening disease caused by Feline Immunodeficiency Virus (FIV), comprising administering to a feline in need of such treatment a vaccine comprising a recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding the envelope protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom.

20. The method of claim 19 wherein said internal gene encodes the FIV envelope protein having the amino acid sequence as set out in Figure 3 or immunogenic fragments thereof.

21. A method for preventing or lessening disease caused by Feline Immunodeficiency Virus (FIV), comprising administering to a feline in need of such treatment a vaccine comprising a recombinant raccoon poxvirus having at least one

internal gene comprising a DNA sequence encoding the gag protein of Feline Immunodeficiency Virus (FIV) or immunogenic fragments therefrom.

22. The method of claim 21 wherein said internal gene encodes the FIV gag protein having the amino acid sequence as set out in Figure 5 or immunogenic fragments thereof.




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/18




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/18

10 20 30 40 50 60
 * * * * * *
 GGATCCAACA ATAATTATGG CAGAAGGATT TGCAGCCAAT AGACAATGGA TAGGACCAGA
 CCTAGGTTGT TATTAATACC GTCTTCCTAA ACGTCGGTTA TCTGTTACCT ATCCTGGTCT
 M A E G F A A N R Q W I G P E>
 70 80 90 100 110 120
 * * * * * *
 AGAACGCTGAA GAGTTATTAG ATTTTGATAT AGCAACACAA ATGAATGAAG AAGGGCCACT
 TCTTCGACTT CTCATAATC TAAAACATA TCGTTGTGTT TACTTACTTC TTCCCGGTGA
 E A E E L L D F D I A T Q M N E E G P L>
 130 140 150 160 170 180
 * * * * * *
 AAATCCAGGG ATGAACCCAT TTAGGGTACCC TGGAATAACA GATAAAGAAA AGCAAGACTA
 TTTAGGTCCC TACTTGGGTAA ATCCCCATGG ACCTTATTGT CTATTTCTTTC TCGTTCTGAT
 N P G M N P F R V P G I T D K E K Q D Y>
 190 200 210 220 230 240
 * * * * * *
 TTGTAAACATA TTACAACCTA AGTTACAAGA TTTACGGAAT GAACTTCAAG AGGTAAAAGT
 AACATTGTAT AATGTTGGAT TCAATGTTCT AAATGCCCTTA CTTGAAGTTC TCCATTGAT
 C N I L Q P K L Q D L R N E L Q E V K L>
 250 260 270 280 290 300
 * * * * * *
 AGAAGAAGGA AATGCAGGTA AGTTAGAAG AACAAAGATTT TTAAGGTATT CTGATGAACA
 TCTTCCTTCTT TTACGTCCAT TCAAATCTTC TTGTTCTAAA AATCCATAA GACTACTTGT
 E E G N A G K F R R T R F L R Y S D E Q>
 310 320 330 340 350 360
 * * * * * *
 AGTATTGTCC CCGGTTCATG CGTTCATAGG ATATTGTATT TATTTAGGTA ATCGAAATAA
 TCATAACAGG GCCAAGTAC GCAAGTATCC TATAACATAA ATAATCCAT TAGCTTTATT
 V L S P V H A F I G Y C I Y L G N R N K>
 370 380 390 400 410 420
 * * * * * *
 GTTAGGATCT TTAAGACATG ACATTGATAT TGAAGCACCC CCCGAAGAGT GTTATGATAA
 CAATCCTAGA AATTCTGTAC TGTAACTATA ACTTCGTGGGG GGGCTTCTCA CAATACTATT
 L G S L R H D I D I E A P P E E C Y D N>
 430 440 450 460 470 480
 * * * * * *
 TAGAGAGAAG GGTACAACTG ACAATATAAA ATATGGTAGA CGATGTTGCC TAGGAACGGT
 ATCTCTCTTC CCATGTTGAC TGTTATATTT TATACCATCT GCTACAAACGG ATCCTTGCCA
 R E K G T T D N I K Y G R R C C L G T V>
 490 500 510 520 530 540
 * * * * * *
 GACTTTGTAC CTGATTTAT TTATAGGATT ATAATATAAT TCACAGACAG CCGACGCTCA
 CTGAAACATG GACTAAATA ATAATCCCTAA TTATTATATA AGTGTCTGTC GGCTGCGAGT
 T L Y L I L F I G L I I Y S Q T A D A Q>

FIG. 3A**SUBSTITUTE SHEET (RULE 26)**

4/18

550	560	570	580	590	600
*	*	*	*	*	*
GGTAGTATGG	AGACTTCAC	CATTAGTAGT	CCCACTAGAA	GAATCAGAAA	TAATTTTG
CCATCATACC	TCTGAAGGTG	GTAATCATCA	GGGTCACTT	CTTAGTCTT	ATTAACAAAC
V V W	R L P	P L V V	P V E	E S E	I I F W>
610	620	630	640	650	660
*	*	*	*	*	*
GGATTGTTGG	GCACCAGAAG	AACCCGCCG	TCAGGACTTT	CTTGGGGCAA	TGATACATCT
CCTAACAAACC	CGTGGTCCTTC	TTGGGCGGAC	AGTCCTGAAA	GAACCCCCTT	ACTATGTAGA
D C W	A P E	E P A C	Q D F	L G A	M I H L>
670	680	690	700	710	720
*	*	*	*	*	*
AAAAGCTAAG	ACAAATATAA	GTATACGAGA	GGGACCTACC	TTGGGGAATT	GGGCTAGAGA
TTTTCGATTC	TGTTTATATT	CATATGCTCT	CCCTGGATGG	AACCCCTTAA	CCCGATCTCT
K A K	T N I	S I R E	G P T	L G N	W A R E>
730	740	750	760	770	780
*	*	*	*	*	*
AATATGGGCA	ACATTATTCA	AAAAGGCTAC	TAGACAATGT	AGAAGAGGCA	GAATATGGAA
TTATACCCGT	TGTAATAAGT	TTTCCGATG	ATCTGTACA	TCTTCTCCGT	CTTATACCTT
I W A	T L F	K K A T	R Q C	R R G	R I W K>
790	800	810	820	830	840
*	*	*	*	*	*
AAGATGGGAT	GAGACTATAA	CAGGACCATC	AGGATGTGCT	AATAACACAT	GTTATAATGT
TTCTACCCCTA	CTCTGATATT	GTCCTGGTAG	TCCTACACGA	TTATTGTGTA	CAATATTACA
R W D	E T I	T G P S	G C A	N N T	C Y N V>
850	860	870	880	890	900
*	*	*	*	*	*
TTCAGCAATA	GTACCTGATT	ATCAGCGTTA	TTTAGATAGA	GTAGATACTT	GGTTACAAGG
AAGTCGTTAT	CATGGACTAA	TAGTCGCAAT	AAATCTATCT	CATCTATGAA	CCAATGTTCC
S A I	V P D	Y Q R Y	L D R	V D T	W L Q G>
910	920	930	940	950	960
*	*	*	*	*	*
GAAAATAAAT	ATATCATTAT	GTCTAACAGG	AGGAAAAATG	TTGTACAATA	AAGTTACAAA
CTTTTATTTA	TATAGTAATA	CAGATTGTCC	TCCTTTTAC	AACATGTTAT	TTCAATGTTT
K I N	I S L	C L T G	G K M	L Y N	K V T K>
970	980	990	1000	1010	1020
*	*	*	*	*	*
ACAATTAAGC	TATTGTACAG	ACCCATTACA	AATCCCCTG	ATCAATTATA	CATTTGGACC
TGTTAACATCG	ATAACATGTC	TGGGTAATGT	TTAGGGTGAC	TAGTTAATAT	GTAAACCTGG
Q L S	Y C T	D P L Q	I P L	I N Y	T F G P>
1030	1040	1050	1060	1070	1080
*	*	*	*	*	*
TAATCAAACA	TGTATGTGGA	ATACTTCACA	AATTCAAGGAC	CCTGAAATAC	CACAATGTGG
ATTAGTTGT	ACATACACCT	TATGAAGTGT	TTAAGTCCTG	GGACTTTATG	GTGTTACACC
N Q T	C M W	N T S Q	I Q D	P E I	P Q C G>

FIG. 3B

5/18

1090	1100	1110	1120	1130	1140
*	*	*	*	*	*
ATGGTGGAAAT	CACATGGCCT	ATTATAACAG	TTGTAATGG	GAAGAGGC	AGGTAAAGTT
TACCACTTA	GTGTACCGGA	TAATATTGTC	AACATTACC	CTTCTCCGTT	TCCATTCAA
W W N	H M A	Y Y N S	C K W	E E A	K V K F>
1150	1160	1170	1180	1190	1200
*	*	*	*	*	*
TCATTGTCAA	AGAACACAGA	GTCAGCCTGG	GTCATGGCGT	AGAGCAACT	CGTCATGGAA
AGTAACAGTT	TCTTGTGTCT	CAGTCGGACC	CAGTACCGCA	TCTCGTTAGA	GCAGTACCTT
H C Q	R T Q	S Q P G	S W R	R A I	S S W K>
1210	1220	1230	1240	1250	1260
*	*	*	*	*	*
ACAAAGAAAT	AGATGGAGT	GGAGACCAGA	TTTGAGAGT	GAAGAGGTGA	AAATATCTCT
TGTTTCTTTA	TCTACCCCTCA	CCTCTGGTCT	AAAACCTCA	CTTTCCACT	TTTATAGAGA
Q R N	R W E	W R P D	F E S	E K V	K I S L>
1270	1280	1290	1300	1310	1320
*	*	*	*	*	*
ACAGTGCAAT	AGCACGAAAA	ACCTAACCTT	TGCAATGAGA	AGTCAGGAG	ATTATGGAGA
TGTACGTTA	TCGTGCTTTT	TGGATTGGAA	ACGTTACTCT	TCAAGTCCTC	TAATACCTCT
Q C N	S T K	N L T F	A M R	S S G	D Y G E>
1330	1340	1350	1360	1370	1380
*	*	*	*	*	*
AGTAACGGGA	GCTTGGATAG	AGTTGGATG	TCATAGAAAT	AAATCAAACC	TTCATACTGA
TCATTGCCCT	CGAACCTATC	TCAAACCTAC	AGTATCTTA	TTAGTTGG	AAGTATGACT
V T G	A W I	E F G C	H R N	K S N	L H T E>
1390	1400	1410	1420	1430	1440
*	*	*	*	*	*
AGCAAGGTTT	AGAATTAGAT	GTAGATGGAA	TGTAGGGAGT	GATACTCGC	TCATTGATAC
TCGTTCCAAA	TCTTAATCTA	CATCTACCTT	ACATCCCTCA	CTATGGAGCG	AGTAACATG
A R F	R I R	C R W N	V G S	D T S	L I D T>
1450	1460	1470	1480	1490	1500
*	*	*	*	*	*
ATGTGGAAAC	ACTCCAAATG	TTTCAGGTGC	GAATCCTGTA	GATTGTACCA	TGTATTCAA
TACACCTTTG	TGAGGTTTAC	AAAGTCCACG	CTTAGGACAT	CTAACATGGT	ACATAAGTT
C G N	T P N	V S G A	N P V	D C T	M Y S N>
1510	1520	1530	1540	1550	1560
*	*	*	*	*	*
TAAAATGTAC	AAGTTTCTT	TACCAAACGG	GTTCACAATG	AAGGTAGATG	ACCTTATTAT
ATTTTACATG	TTCAAAAGAA	ATGGTTGCC	CAAATGTAC	TTCCCATCTAC	TGGAATAATA
K M Y	K F S	L P N G	F T M	K V D	D L I M>
1570	1580	1590	1600	1610	1620
*	*	*	*	*	*
GCATTTCAAT	ATGCCAAAAG	CTGTAGAAAT	GAATAATATT	GCTGGAAATT	GGTCTTGTAC
CGTAAAGTTA	TACGGTTTTC	GACATCTTA	CTTATTATAA	CGACCTTAA	CCAGAACATG
H F N	M P K	A V E M	N N I	A G N	W S C T>

FIG. 3C

SUBSTITUTE SHEET (RULE 26)

6/18

1630	1640	1650	1660	1670	1680
*	*	*	*	*	*
ATCTGACTTG	CCATCGTCAT	GGGGGTATAT	GAATTGTAAT	TGCCCAAATA	GTAGTAGTAG
TAGACTGAAC	GGTAGCAGTA	CCCCCATATA	CTTAACATTA	ACGGGTTTAT	CATCATCATC
S D L P S S	W G Y M	N C N C P N	S S S S >		
1690	1700	1710	1720	1730	1740
*	*	*	*	*	*
TTATAGTGGT	ACTAAAATGG	CATGTCCTAG	CAATCGAGGC	ATCTTAAGGA	ATTGGTATAAA
AATATCACCA	TGATTTTACC	GTACAGGATC	GTTAGCTCCG	TAGAATTCCCT	TAACCATATT
Y S G T K M	A C P S	N R G	I L R	N W Y	N >
1750	1760	1770	1780	1790	1800
*	*	*	*	*	*
CCCAGTAGCA	GGATTACCGAC	AATCCTTAGA	ACAGTATCAA	GTTGTAAAAC	AACCAGATTA
GGGTCTCATCGT	CCTAATGCTG	TTAGGAATCT	TGTCATAGTT	CAACATTTG	TTGGTCTAAT
P V A G L R	Q S L E	Q Y Q	V V K	Q P D	Y >
1810	1820	1830	1840	1850	1860
*	*	*	*	*	*
CTTACTGGTC	CCAGAGGAAG	TCATGGAATA	TAAACCTAGA	AGGAAAAGGG	CAGCTATTCA
GAATGACCAG	GGTCTCCTTC	AGTACCTTAT	ATTTGGATCT	TCCTTTCCC	GTCGATAAGT
L L V P E E	V M E Y	K P R	R K R	A A I	H >
1870	1880	1890	1900	1910	1920
*	*	*	*	*	*
TGTTATGTTG	GCTCTTGCCT	CAGTATTATC	TATTGCCGT	GCAGGGACGG	GGGCTACTGC
ACAATACAAC	CGAGAACGTT	GTCATAATAG	ATAACGGCCA	CGTCCCTGCC	CCCGATGACG
V M L A L A	T V L S	I A G	A G T	G A T	A >
1930	1940	1950	1960	1970	1980
*	*	*	*	*	*
TATAGGGATG	GTAACACAAT	ACCACCAAGT	TCTGGCAACC	CATCAAGAAT	CTATGGAAAA
ATATCCCTAC	CATTGTGTTA	TGGTGGTTCA	AGACCGTTGG	GTAGTTCTTA	GATACCTTT
I G M V T Q	Y H Q V	L A T H Q E	S M E K >		
1990	2000	2010	2020	2030	
*	*	*	*	*	SpeI
GGTGACTGAA	GCCTTAGAGA	AAAACAACCT	AAGGTTAGTT	ACATTAGAGC	ATCAAGTACT
CCACTGACTT	CGGAATCTCT	ATTTGTTGA	TTCCAATCAA	TGTAATCTCG	TAGTTCATGA
V T E A L E	I N N L	R L V	T L E	H Q V	L >
2050	2060	2070	2080	2090	2100
*	*	*	*	*	*
AGTAATAGGA	TTAAAAGTAG	AAGCTATGGA	AAAATTTTA	TATACAGCTT	TCGCTATGCA
TCATTATCCT	AATTTTCATC	TTCGATAACCT	TTTAAAAAT	ATATGTCGAA	AGCGATACGT
V I G L K V	E A M E	K F L	Y T A F A M	Q >	

FIG. 3D

7/18

2110	2120	2130	2140	2150	2160
*	*	*	*	*	*
AGAATTAGGA	TGTAATCCAA	ATCAATTTT	CTCCAAAATC	CCTCTTGAGT	TGTGGACAAG
TCTTAATCCT	ACATTAGGTT	TAGTTAAAAA	GAGGTTTAG	GGAGAACTCA	ACACCTGTTC
E L G	C N P	N Q F F	S K I	P L E	L W T R>
2170	2180	2190	2200	2210	2220
*	*	*	*	*	*
GTATAATATG	ACTATAAAC	AAACAATATG	GAATCATGGA	AATATAACTT	TGGGGGAATG
CATATTATAC	TGATATTTAG	TTTGTATAC	CTTAGTACCT	TTATATTGAA	ACCCCCCTAC
Y N M	T I N	Q T I W	N H G	N I T	L G E W>
2230	2240	2250	2260	2270	2280
*	*	*	*	*	*
GTATAACCAC	ACCAAAGATT	TACAACAAA	GTTTTATGAA	ATAATAATGG	ACATAGAAC
CATATTGGTG	TGGTTCTAA	ATGTTGGTT	CAAAATACTT	TATTATTACC	TGTATCTGG
Y N H	T K D	L Q P K	F Y E	I I M	D I E P>
2290	2300	2310	2320	2330	2340
*	*	*	*	*	*
AAATAATGTA	CAAGGGAAAA	CAGGGATACA	ACAATTACCC	AAGTGGGAAG	ATTGGGTAAG
TTTATTACAT	GTTCCTTTT	GTCCCTATGT	TGTTAATGGG	TTCACCCCTTC	TAACCCATTC
N N V	Q G K	T G I Q	Q L P	K W E	D W V R>
2350	2360	2370	2380	2390	2400
*	*	*	*	*	*
ATGGATAGGA	AATATTCCAC	AATATTTAAA	GGGACTATTG	GGAGGTATCT	TGGGAATAGG
TACCTATCCT	TTATAAGGTG	TTATAAATT	CCCTGATAAC	CCTCCATAGA	ACCCTTATCC
W I G	N I P	Q Y L K	G L L	G G I	L G I G>
2410	2420	2430	2440	2450	2460
*	*	*	*	*	*
ATTAGGAGTG	TTATTATTGA	TTTTATGTTT	ACCTACATTG	GTTGATTGTA	TAAGAAATTG
TAATCCTCAC	AATAATAACT	AAAATACAAA	TGGATGTAAC	CAACTAACAT	ATTCTTTAAC
L G V	L L L	I L C L	P T L	V D C	I R N C>
2470	2480	2490	2500	2510	2520
*	*	*	*	*	*
TATCCACAAAG	ATACTAGGAT	ACACAGTAAT	TGCAATGCCT	GAAGTAGAAG	GAGAAGAAAT
ATAGGTGTT	TATGATCCTA	TGTGTCTTA	ACGTTACGGA	CTTCATCTTC	CTCTTCTTTA
I H K	I L G	Y T V I	A M P	E V E	G E E I>
2530	2540	2550	2560	2570	2580
*	*	*	*	*	*
ACAACCACAA	ATGGAATTGA	GGAGAAATGG	TAGCCAATT	GGCATGTCTG	AAAAAGAGGA
TGTTGGTGT	TACCTTAACT	CCTCTTTACC	ATCGGTTAAA	CCGTACAGAC	TTTTCTCCT
Q P Q	M E L	R R N G	S Q F	G M S	E K E E>
2590	2600	2610	2620	2630	2640
*	*	*	*	*	*
GGAATGATGA	AGTATCTCAG	ACTTATTTA	TAAGGGAGAT	ACTGTGCTAA	GTCTCCCT
CCTTACTACT	TCATAGAGTC	TGAATAAAAT	ATTCCCTCTA	TGACACGATT	CAAGAAGGGA
E>					

FIG. 3E

8/18

2650	2660	2670	2680	2690	2700
TTGAGGAAGG TATGTCATAT GAATCCATT CGAACCAAAT CAAACTAATA AAGTATGTAT AACTCCTTCC ATACAGTATA CTTAGGTAAA GCTTGGTTA GTTTGATTAT TTCATACATA					
2710	2720	2730	2740	2750	2760
TGTAAGGTA AAGGAAAAGA CAAAGAAGAA GAAGAAAAGA GAAAGCTTTC AAGAGGATGA ACATTCCATT TTCCCTTTCT GTTCTTCTT CTTCTTCTT CTTCGAAAG TTCTCCTACT					
2770	2780	2790	2800	2810	2820
TGACAGAGTT AGAAGATCGC TTCAAGGAAGC TATTTGGCAC GACTTCTACA ACGGGAGACA ACTGTCTCAA TCTTCTAGCG AAGTCCTTCG ATAAACCGTG CTGAAGATGT TGCCCTCTGT					
2830	2840	2850	2860	2870	2880
GCACAGTAGA TTCTGAAGAT GAACCTCCTA AAAAAGAAAA AAGGGTGGAC TGGGATGAGT CGTGTCACTCT AAGACTTCTA CTTGGAGGAT TTTTCTTT TTCCCACCTG ACCCTACTCA					
2890	2900	2910	2920	2930	2940
ATTGGAACCC TGAAGAAATA GAAAGAATGC TTATGGACTA GGGACTGTTT ACGAACAAAT TAACCTTGGG ACTTCTTAT CTTCTTACG AATAACCTGAT CCCTGACAAA TGCTTGTAA					
2950	2960	2970	2980	2990	3000
GATAAAAGGA AATAGCTAAG CATGACTCAT AGTTAAAGCG CTAGCAGCTG CTTAACCGCA CTATTTCCCT TTATCGATTG GTACTGAGTA TCAATTTCGC GATCGTCGAC GAATTGGCGT					
3010	3020	3030	3040	3050	3060
AAACCACATC CTATGTAAG CTTGCTAATG ACGTATAAGT TGTCCATTG TAAGAGTATA TTGGGTGTAG GATACATTTC GAACGATTAC TGCAATTCA ACAAGGTAAC ATTCTCATAT					
3070	3080	3090	3100	3110	3120
TAACCAGTGC TTTGTGAAAC TTCAAGGAGT CTCCTCCGTG AGGACTTTCG AGTTCTCCCT ATTGGTCACG AAACACTTTC AAGCTCCTCA GAGAGGCAAC TCCTGAAAGC TCAAGAGGGA					
3130	3140	3150	3160	3170	3180
TGAGGCTCCC ACAGATACAA TAAATATTTG AGATTGAACC CTGTCAAGTA TCTGTGTAAT ACTCCGAGGG TGTCTATGTT ATTATAAAC TCTAACTTGG GACAGTTCAT AGACACATTA					
3190	3200	3210	3220		
CTTTTTTACCG TGTGAGGTCT CGGAATCCGG GCCGAGAACT TCGCA GAAAAAAATGG ACACCTCCAGA GCCTTAGGCC CGGCTCTTGA AGCGT					

FIG. 3F

9/18




FIG. 4

SUBSTITUTE SHEET (RULE 26)

10/18

10 20 30 40 50 60

* * * * *

ATGGGGAAATG GACAGGGGGCG AGATGGAAA ATGGCCATTAGAGATGTAG TAATGCTGCT
 TACCCCTTAC CTGTCCCCCGC TCTAACCTTT TACCGGTAAT TCTCTACATC ATTACGACGA
 M G N G Q G R D W K M A I K R C S N A A >
 ---> p15 Matrix protein

70 80 90 100 110 120

* * * * *

G TAGGAGTAG GGGGGAAAGAG TAAAAAATTT GGGGAAGGGA ATTTCA GATG GCCATTAGA
 CATCCTCATC CCCCTTCTC ATTTTTAAA CCCCTCCCT TAAAGTCTAC CCGGTAATCT
 V G V G G K S K K F G E G N F R W A I R >

130 140 150 160 170 180

* * * * *

ATGGCTAATG TATCTACAGG ACGAGAACCT GGTGATATAC CAGAGACTTT AGATCAACTA
 TACCGATTAC ATAGATGTCC TGCTCTGGGA CCACTATATG GTCTCTGAAA TCTAGTTGAT
 M A N V S T G R E P G D I P E T L D Q L >

190 200 210 220 230 240

* * * * *

AGGTTGGTTA TTGCGATT ACAAGAAAGA AGAAAAAAAT TTGGATCTTG CAAAGAAATT
 TCCAACCAAT AAACGCTAAA TGTTCTTCT TCTTTTTTA AACCTAGAAC GTTTCTTAA
 R L V I C D L Q E R R K K F G S C K E I >

250 260 270 280 290 300

* * * * *

GATAAGCAA TTGTTACATT AAAAGCTTT GCGGCAGTAG GACTTTAAA TATGACAGTG
 CTATTCCGTT AACAATGTAA TTTTCAGAAA CGCCGTCATC CTGAAAATTT ATACTGTCAC
 D K A I V T L K V F A A V G L L N M T V >

310 320 330 340 350 360

* * * * *

TCTTCTGCTG CTGCAGCTGA AAATATGTT ACTCAGATGG GATTAGACAC TAGACCAC
 AGAAGACGAC GACGTCGACT TTTATACAAG TGAGTCTACC CTAATCTGTG ATCTGGTAGA
 S S A A A A E N M F T Q M G L D T R P S >

370 380 390 400 410 420

* * * * *

ATGAAAGAAG CAGGAGGAAA AGAGGAAGGC CCTCCACAGG CATTCTAT TCAAACAGTA
 TACTTTCTTC GTCCCTCTT TCTCCTCCG GGAGGTGTCC GTAAAGGATA AGTTTGTCT
 M K E A G G K E E G P P Q A F P I Q T V >
 p15 <----- -----> p25

Capsid protein

430 440 450 460 470 480

* * * * *

AATGGAGTAC CACAATATGT AGCACTTGAC CCAAAATGG TGTCCATT TATGGAAAAG
 TTACCTCATG GTGTTATACA TCGTGAAC TG GTTTTAC ACAGGTAAGA ATACCTTTTC
 N G V P Q Y V A L D P K M V S I F M E K >

490 500 510 520 530 540

* * * * *

GCAAGAGAAG GATTAGGAGG TGAGGAAGTT CAGCTATGGT TCACTGCCTT CTCTGCAAAT
 CGTTCTCTTC CTAATCCTCC ACTCCTCAA GTCGATACCA AGTGACGGAA GAGACGTTA
 A R E G L G G E E V Q L W F T A F S A N >

FIG. 5A**SUBSTITUTE SHEET (RULE 26)**

11/18

550 * 560 * 570 * 580 * 590 * 600 *
 TTAACACCTA CTGACATGGC CACATTAATA ATGGCCGCAC CAGGGTGCAC TGCAGATAAA
 AATTGTGGAT GACTGTACCG GTGTAATTAT TACCGGGTGTG GTCCCCACGCG ACGTCTATTT
 L T P T D M A T L I M A A P G C A A D K>

610 * 620 * 630 * 640 * 650 * 660 *
 GAAATATTGG ATGAAAGCTT AAAGCAACTT ACTGCAGGAT ATGATCGTAC ACATCCCCCT
 CTTTATAACC TACTTCGAA TTTCGTTGAA TGACGTCTA TACTAGCATG TGTAGGGGA
 E I L D E S L K Q L T A G Y D R T H P P>
 M I V H I P L>

670 * 680 * 690 * 700 * 710 * 720 *
 GATGCTCCC A GACCATTACC CTATTTACT GCAGCAGAAA TTATGGGTAT TGGATTACT
 CTACGGGGT CTGGTAATGG GATAAAATGA CGTCGTCTT AATACCCATA ACCTAAATGA
 D A P R P L P Y F T A A E I M G I G F T>
 M L P D H Y P I L L Q Q K L W V L D L L>

730 * 740 * 750 * 760 * 770 * 780 *
 CAAGAACAAAC AAGCAGAAC AAGATTTGCA CCAGCTAGGA TGCAGTGTAG AGCATGGTAT
 GTTCTGTTG TCGTCTTCG TTCTAACGT GGTCGATCCT ACGTACATC TCGTACCCATA
 Q E Q Q A E A R F A P A R M Q C R A W Y>
 K N N K Q K Q D L H Q L G C S V E H G I>

790 * 800 * 810 * 820 * 830 * 840 *
 CTCGAGGGAC TAGGAAAAATT GGGGCCATA AAAGCTAAGT CTCCCTCGAGC TGTGCAGTTA
 GAGCTCCCTG ATCCTTTAA CCCGGGTAT TTTCGATTCA GAGGAGCTCG ACACGTCAT
 L E G L G K L G A I K A K S P R A V Q L>
 S R D>

850 * 860 * 870 * 880 * 890 * 900 *
 AGACAAGGAG CTAAGGAAGA TTATTCACTT TTTATTGACA GATTGTTTG CCAAATAGAT
 TCTGTTCTC GATTCTTCT AATAAGTAGG AAATAACTGT CTAACAAACG GGTTTATCTA
 R Q G A K E D Y S S F I D R L F A Q I D>

910 * 920 * 930 * 940 * 950 * 960 *
 CAAGAACAAA ATACAGCTGA AGTTAAGTTA TATTTAAAAC AGTCATTAAG CATGGCTAAT
 GTTCTTGTGTT TATGTCGACT TCAATTCAAT ATAAAATTG TCAGTAATTG GTACCGATTA
 Q E Q N T A E V K L Y L K Q S L S M A N>

970 * 980 * 990 * 1000 * 1010 * 1020 *
 GCTAATGCAG AATGTAAAAA GCCAATGACC CACCTTAAGC CAGAAAGTAC CCTAGAAGAA
 CGATTACGTC TTACATTTT CGGTTACTGG GTGGAATTG GTCTTCATG GGATCTTCTT
 A N A E C K K P M T H L K P E S T L E E>

FIG. 5B**SUBSTITUTE SHEET (RULE 26)**

12/18

1030	1040	1050	1060	1070	1080
*	*	*	*	*	*
AAGTTGAGAG	CTTGTCAAGA	AATAGGCTCA	CCAGGGATATA	AAATGCAACT	CTTGGCAGAA
TTCAACTCTC	GAACAGTTCT	TTATCCGAGT	GGTCCTATAT	TTTACGTTGA	GAACCGTCTT
K L R	A C Q E	I G S	P G Y	K M Q L	L A E>
				p25 <-----	-----> p10
					Nucleocapsid
1090	1100	1110	1120	1130	1140
*	*	*	*	*	*
GCTCTTACAA	AAGTTCAAGT	AGTGCAATCA	AAAGGGATCAG	GACCAGTGTG	TTTTAATTGT
CGAGAAATGTT	TTCAAGTTCA	TCACGTTAGT	TTTCCTAGTC	CTGGTCACAC	AAAATTAACA
A L T	K V Q V	V Q S	K G S	G P V C	F N C>
1150	1160	1170	1180	1190	1200
*	*	*	*	*	*
AAAAAAACCAAG	GACATCTAGC	AAGACAATGT	AGAGAAAGTGA	AAAAATGTAA	TAAATGTGGA
TTTTTGTC	CTGTAGATCG	TTCTGTTACA	TCTCTTCACT	CTTTTACATT	ATTTACACCT
K K P	G H L A	R Q C	R E V	R K C N	X C G>
1210	1220	1230	1240	1250	1260
*	*	*	*	*	*
AAACCTGGTC	ATGTAGCTGC	CAAATGTTGG	CAAGGAAATA	GAAAGAATTG	GGGAAACTGG
TTTGGACCAAG	TACATCGACG	GTTTACAACC	GTTCCCTTAT	CTTTCTTAAG	CCCTTTGACCC
K P G	H V A A	K C W	Q G N	R K N S	G N W>
1270	1280	1290	1300	1310	1320
*	*	*	*	*	*
AAGGCCGGGC	GAGCTGCAGC	CCCAGTGAAT	CAAGTGCAGC	AAGCAGTAAT	GCCATCTGCA
TTCCGCCCG	CTCGACGTGG	GGGTCACTTA	GTTCACGTCG	TTCGTCATTA	CGGTAGACGT
K A G	R A A A	P V N	Q V Q	Q A V M	P S A>
1330	1340	1350			
*	*	*			
CCTCCAATGG	AGGAGAAACT	ATTGGATTAA	TAA		
GGAGGTTACC	TCCTCTTGA	TAACCTAAAT	ATT		
P P M	E E K L	L D L>			

p10 ----->

FIG. 5C

13/18




FIG. 6

SUBSTITUTE SHEET (RULE 26)




FIG. 7

SUBSTITUTE SHEET (RULE 26)

15/18




FIG. 8

SUBSTITUTE SHEET (RULE 26)

16/18

Cat ID	Vaccination Route	Pre Challenge Viremia •	CD4:CD8	1 Month Post Challenge		3 Month Post Challenge Viremia •	CD4:CD8	9 Month Post Challenge Viremia •		CD4:CD8
				CD4:CD8	Viremia •			CD4:CD8	Viremia •	
RCMV-FIV gag Vaccines										
AQJ3	SC	NEG	2.70	NEG	1.82	POS	0.30	NA	0.61	
AQD4	SC	NEG	3.62	NEG	1.71	POS	2.18	POS	1.18	
ATF1	SC	NEG	3.80	NEG	3.87	POS	1.08	POS	1.12	
ATH3	SC	NEG	1.93	NEG	3.26	POS	0.40	DEAD	0.94	
AT1	SC	NEG	3.23	NEG	2.17	POS	1.12	POS	0.86	
AQE4	IM	NEG	3.37	NEG	2.95	POS	1.24	NEG	1.19	
AQT4	IM	NEG	1.59	NEG	3.68	POS	1.44	NA	0.79	
AQY4	IM	NEG	2.41	NEG	3.86	POS	0.64	POS	0.77	
ATJ2	IM	NEG	3.63	NEG	3.28	POS	1.49	POS	1.67	
ATJ1	IM	NEG	3.27	NEG	3.73	POS	1.05	POS	1.11	
RCMV-FIV envAB Vaccines										
ARB4	SC	NEG	2.72	NEG	2.12	NEG	2.27	NEG	1.65	
ARO2	SC	NEG	3.20	NEG	2.26	POS	0.67	POS	1.18	
ATJ4	SC	NEG	2.16	NEG	2.54	POS	0.60	POS	0.76	
ATK1	SC	NEG	3.06	NEG	2.27	POS	0.90	POS	0.74	
ATL1	SC	NEG	2.32	POS	3.46	POS	1.16	POS	1.44	
ARD4	IM	NEG	3.04	POS	2.29	POS	1.07	POS	1.04	
ARE4	IM	NEG	2.20	POS	2.89	POS	1.23	POS	1.00	
ARG4	IM	NEG	2.48	NEG	2.79	POS	1.25	NA	1.02	
ATL2	IM	NEG	3.44	POS	2.63	POS	1.16	POS	1.04	
ATL3	IM	NEG	2.44	NEG	3.14	POS	1.30	POS	1.06	
RCMV-FIV envAB + RCMV-FIV gag Vaccines										
ARN4	SC	NEG	3.04	NEG	2.73	NEG	1.88	POS	1.11	
ARO2	SC	NEG	3.14	POS	3.09	POS	0.41	POS	0.57	
ARO3	SC	NEG	2.76	NEG	4.11	POS	0.77	POS	0.74	
ATL4	SC	NEG	2.55	NEG	3.43	NEG	0.80	POS	0.88	
ATM1	SC	NEG	3.78	NEG	2.57	POS	0.67	POS	0.81	
Wild Type RCMV Vaccines(Controls)										
ARQ4	SC	NEG	2.87	NEG	2.54	NEG	0.55	POS	0.86	
ARR4	SC	NEG	2.29	POS	1.93	POS	0.77	POS	0.70	
ATM2	SC	NEG	2.64	NEG	1.69	POS	0.92	POS	0.93	
ATM3	SC	NEG	3.91	POS	2.90	POS	0.62	POS	0.78	
ATN1	SC	NEG	3.01	POS	3.62	POS	1.09	POS	0.99	

NA = Not Available due to Contaminated Culture
 SC = Subcutaneous Vaccination
 IM = Intramuscular Vaccination

CD4:CD8 = Ratio of CD4 Positive Lymphocytes to CD8 Positive Lymphocytes as Measured by Flow Cytometry

FIG. 9

* Viremia Detected by Culture Isolation of FIV from Peripheral Blood Mononuclear Cells

17/18

Time Point After Challenge	Group	% of Cats Viremic	Preventable Fraction*	% of Cats CD4:CD8 <1.0	Preventable Fraction†
1 Months	Controls	60%	0%	0%	0%
	RCNV-FIV gag	0%	100%	0%	NA
	RCNV-FIV envAB	40%	33%	0%	NA
	RCNV-FIV gag + envAB	20%	67%	0%	NA
3 Months	Controls	80%	0%	80%	63%
	RCNV-FIV gag	100%	0%	30%	63%
	RCNV-FIV envAB	90%	0%	30%	63%
	RCNV-FIV gag + envAB	60%	25%	40%	50%
9 Months	Controls	100%	0%	100%	50%
	RCNV-FIV gag	86%	14%	50%	50%
	RCNV-FIV envAB	89%	11%	20%	80%
	RCNV-FIV gag + envAB	100%	0%	80%	20%

*Preventable Fraction = [(% Controls with Sign) - (% Vaccinates with Sign)] + (% Controls with Sign) x 100

FIG. 10

18/18

FIG. 11

Cat ID	Vaccination Route	Depression	Ocular Discharge	Nasal Discharge	Dyspnea	Fever	Total Score
RCNV-FIV Gap Vaccinates							
AQC3	SC	0	0	0	0	0	8
AQD4	SC	1	0	0	0	5	6
ATF1	SG	0	0	0	0	2	2
ATH3	SC	DEAD	0	0	0	DEAD	DEAD
ATII	SC	0	0	1	8	4	13
AQE4	IM	0	1	1	28	5	35
AQT4	IM	0	1	2	0	2	5
AQY4	IM	0	0	0	0	7	7
ATI2	IM	0	1	0	0	3	4
ATJ1	IM	0	0	0	0	3	3
Average		0.1	0.3	0.4	4.0	4.3	9.2
% Reduction		0%	86%	0%	55%	0%	41%
RCNV-FIV envA B Vaccinates							
ARB4	SC	0	0	0	0	15	15
ARO2	SC	0	0	1	4	1	6
ATJ4	SC	0	0	0	4	5	9
ATK1	SC	0	1	0	0	7	8
ATL1	SC	0	0	0	4	0	4
ARD4	IM	0	0	0	0	-1	1
ARE4	IM	0	0	0	0	1	1
ARG4	IM	0	0	0	12	0	12
ATL2	IM	0	0	0	0	9	9
ATL3	IM	0	1	0	0	0	1
Average		0.0	0.2	0.1	2.4	3.9	6.6
% Reduction		0%	92%	75%	73%	3%	58%
Wild Type RCNV Vaccinates (Controls)							
ARQ4	SC	0	2	0	0	0	2
ARR4	SC	0	0	0	0	12	12
ATM2	SC	0	1	1	12	0	14
ATM3	SC	0	9	1	32	7	49
ATN1	SC	0	0	0	0	1	1
Average		0.0	2.4	0.4	8.8	4.0	15.6

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/08508A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K48/00 C12N15/86 C12N15/49 //A61K39/12, A61K39/118

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,94 06471 (PITMAN MOORE, INC.) 31 March 1994	1-9,19, 20
A	see page 22, line 17 - page 23, line 8; figure 1	10-18, 21,22
Y	WO,A,94 02613 (PITMAN MOORE, INC.) 3 February 1994	1,4,5,8, 9,19
A	see page 17, line 13 - page 18, line 8; claim 15	2,3,6,7, 10-18, 20-22
Y	WO,A,92 15684 (CAMBRIDGE BIOTECH CORP.) 17 September 1992	1-22
	see examples 1-3	
Y	EP,A,0 652 287 (AMERICAN HOME PRODUCTS CORP.) 10 May 1995	1-22
	see the whole document	

	-/-	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 October 1996

25. 10. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Olson, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/08508

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,5 266 313 (ESPOSITO J.J. AND G.M. BAER) 30 November 1993 see the whole document ---	1-22
A	REVIEWS IN MEDICAL MICROBIOLOGY, vol. 4, 1993, pages 80-88, XP000600230 BAXBY, D.: "Recombinant poxvirus vaccines" see abstract -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/US 96/08508

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9406471	31-03-94	AU-A-	4826493	12-04-94
		CA-A-	2143187	31-03-94
		EP-A-	0661999	12-07-95
		JP-T-	8504090	07-05-96
		ZA-A-	9306970	29-08-94
WO-A-9402613	03-02-94	AU-A-	4569393	14-02-94
		ZA-A-	9305122	07-02-94
WO-A-9215684	17-09-92	CA-A-	2104285	29-08-92
		EP-A-	0573616	15-12-93
		JP-T-	6505639	30-06-94
EP-A-0652287	10-05-95	AU-A-	7411694	06-04-95
		CA-A-	2132374	23-03-95
		JP-A-	7184662	25-07-95
		NZ-A-	264518	25-06-96
US-A-5266313	30-11-93	US-A-	5348741	20-09-94